九洲药业1月15日获融资买入5327.01万元，融资余额5.12亿元

Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical has shown positive financial performance with a notable increase in revenue and net profit, alongside significant trading activity in its stock [1][2][3] Group 2 - As of January 15, Jiuzhou Pharmaceutical's stock price increased by 0.66%, with a trading volume of 366 million yuan. The financing buy-in amount for the day was 53.27 million yuan, while the financing repayment was 45.71 million yuan, resulting in a net financing buy of 7.56 million yuan [1] - The total balance of margin trading for Jiuzhou Pharmaceutical reached 513 million yuan, with the financing balance accounting for 2.92% of the circulating market value, indicating a high level compared to the past year [1] - The company reported a revenue of 4.16 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 4.92%, and a net profit attributable to shareholders of 748 million yuan, which is an 18.51% increase year-on-year [2] - Jiuzhou Pharmaceutical has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for Jiuzhou Pharmaceutical increased to 59,200, a rise of 10.22%, while the average circulating shares per person decreased by 9.27% to 15,035 shares [2][3]